Last reviewed · How we verify
NCT03184727
Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay Disease
trial in COPD in 600 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 15 June 2017 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across China |
Conditions studied
- COPD — all drugs for COPD →
- Pulmonary Vascular Disorder — all drugs for Pulmonary Vascular Disorder →
- Right Ventricular Dysfunction — all drugs for Right Ventricular Dysfunction →
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Who can join
40 and older, any sex, with COPD or Pulmonary Vascular Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The pulmonary vasculopathy and right heart dysfunction in COPD are drawing increasing attention these days. Recent researches show that pulmonary vasculopathy and right heart dysfunction relate to greater severity in COPD. Applying appropriate modalities for early detection of pulmonary vasculopathy and right heart dysfunction is of great importance. What's more, the interaction mechanism between pulmonary vasculature, right heart and COPD still needs to be further studied. The aim of our study is to develop an assessment system of pulmonary vasculopathy and right heart dysfunction in COPD patients and elucidate their impact on COPD course and outcome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03184727
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COPD
Currently open trials in the same condition.
- NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
- NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
- NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
Other Chinese Academy of Medical Sciences, Fuwai Hospital trials
Trials by the same sponsor.
- NCT07450196 — A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Val · not yet recruiting
- NCT07511309 — FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07054541 — A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire · Phase 4 · not yet recruiting
- NCT07458672 — TAVR for Aortic Regurgitation Under TTE Guidance · NA · not yet recruiting
- NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03184727 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences, Fuwai Hospital
- Last refreshed: 14 June 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03184727.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing